Long-Term Follow-up of Multiple Myeloma Patients Treated by Bortezomib (Velcade®): A Study on Efficacy, Tolerance, Survival and Time to Progression
Mauricette Michallet(Université Claude Bernard Lyon 1), Jacques Troncy(Hôpital Edouard Herriot), Aline Praire(Centre Hospitalier Universitaire de Toulouse), Giovanna Cannas(Hôpital Edouard Herriot), Quoc Hung Le(Hôpital Edouard Herriot), Claudiu Plesa(Institut Mérieux (France)), Fiorenza Barraco(Hôpital Lyon Sud), Youcef Chelghoum(Hôpital Edouard Herriot), Xavier Thomas(Hôpital Lyon Sud), Mohamad Sobh(Ottawa Hospital), Charles Dumontet(Centre de Recherche en Cancérologie de Lyon), Franck E. Nicolini(Hôpital Edouard Herriot), Emmanuelle Nicolas‐Virelizier(Hôpital Edouard Herriot)
Cited by 0
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547